223 related articles for article (PubMed ID: 19407109)
1. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis.
Sundar S; Singh A; Agarwal D; Rai M; Agrawal N; Chakravarty J
Am J Trop Med Hyg; 2009 May; 80(5):700-3. PubMed ID: 19407109
[TBL] [Abstract][Full Text] [Related]
2. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
Sundar S; Chakravarty J; Agarwal D; Shah A; Agrawal N; Rai M
Trop Med Int Health; 2008 Sep; 13(9):1208-12. PubMed ID: 18664241
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
[TBL] [Abstract][Full Text] [Related]
4. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
Sundar S; Chakravarty J; Rai VK; Agrawal N; Singh SP; Chauhan V; Murray HW
Clin Infect Dis; 2007 Sep; 45(5):556-61. PubMed ID: 17682988
[TBL] [Abstract][Full Text] [Related]
6. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
Singh GP; Saxena RK; Priyadarshy V
J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B therapy in kala-azar.
Giri OP
J Indian Med Assoc; 1993 Apr; 91(4):91-3. PubMed ID: 8409490
[TBL] [Abstract][Full Text] [Related]
9. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.
Sundar S; Goyal AK; Mandal AK; Makharia MK; Singh VP; Murray HW
J Assoc Physicians India; 1999 Feb; 47(2):186-8. PubMed ID: 10999086
[TBL] [Abstract][Full Text] [Related]
12. Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
[TBL] [Abstract][Full Text] [Related]
13. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
14. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
[TBL] [Abstract][Full Text] [Related]
15. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
[TBL] [Abstract][Full Text] [Related]
16. Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study.
Sundar S; Singh A; Rai M; Chakravarty J
Am J Trop Med Hyg; 2015 Mar; 92(3):513-7. PubMed ID: 25510715
[TBL] [Abstract][Full Text] [Related]
17. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.
Syriopoulou V; Daikos GL; Theodoridou M; Pavlopoulou I; Manolaki AG; Sereti E; Karamboula A; Papathanasiou D; Krikos X; Saroglou G
Clin Infect Dis; 2003 Mar; 36(5):560-6. PubMed ID: 12594635
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.
Sundar S; Pandey K; Thakur CP; Jha TK; Das VN; Verma N; Lal CS; Verma D; Alam S; Das P
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3169. PubMed ID: 25233346
[TBL] [Abstract][Full Text] [Related]
19. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.
Jha TK; Sundar S; Thakur CP; Felton JM; Sabin AJ; Horton J
Am J Trop Med Hyg; 2005 Dec; 73(6):1005-11. PubMed ID: 16354802
[TBL] [Abstract][Full Text] [Related]
20. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
Berman J
Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
[No Abstract] [Full Text] [Related]
[Next] [New Search]